Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Revenue (2023 - 2025)

Immunocore Holdings' Revenue history spans 3 years, with the latest figure at $104.5 million for Q4 2025.

  • For Q4 2025, Revenue rose 24.3% year-over-year to $104.5 million; the TTM value through Dec 2025 reached $400.0 million, up 28.95%, while the annual FY2025 figure was $400.0 million, 28.95% up from the prior year.
  • Revenue for Q4 2025 was $104.5 million at Immunocore Holdings, up from $103.7 million in the prior quarter.
  • Across five years, Revenue topped out at $104.5 million in Q4 2025 and bottomed at $54.7 million in Q1 2023.
  • The 3-year median for Revenue is $77.8 million (2024), against an average of $80.0 million.
  • The largest annual shift saw Revenue grew 19.8% in 2024 before it skyrocketed 33.16% in 2025.
  • A 3-year view of Revenue shows it stood at $70.2 million in 2023, then grew by 19.8% to $84.1 million in 2024, then rose by 24.3% to $104.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Revenue are $104.5 million (Q4 2025), $103.7 million (Q3 2025), and $98.0 million (Q2 2025).